Grow Life 420

At the Green Market Report Midwest Women’s Cannabis Business Summit in Chicago on Nov. 2, we recognized some of the stellar industry players with the GMR Midwest Women in Cannabis Awards.

The trailblazer award went to Jackie Cahan, managing partner at Chicago-based ancillary logistics firm 240L Holdings, which specializes in supply chain solutions for marijuana companies.

Cahan is relatively new to the marijuana business, having just launched 240L in early 2021, but after just a few years she says she feels like a “seasoned veteran.”

“I didn’t know that I that I needed the cannabis business,” Cahan told Green Market Report, but during the COVID pandemic, the stress led to alcohol abuse for her, and it was cannabis that helped her quit drinking. “I really credit cannabis with saving my life, dropping the bottle, and really trying to understand what my body needs in order to be an optimum human.”

Cahan’s company made its first acquisition the summer after it launched: a distribution company in Oregon that Cahan helped reorganize into a far more efficient brand managing machine.

“Just ripping that business apart” was one of her proudest moments to date, Cahan said, because it helped her come up with an inventory management system she calls the “doobie decimal system,” and used it to organize more than a million SKUs.

“Now being able to actually track and trace SKUs, to be able to provide our brands with dashboards that tell them how their goods are performing on the shelf at the retailer, is then a pretty empowering moment for the supply chain,” Cahan said.

She added that she’s been surprised by how difficult it’s been to get colleagues in the marijuana trade to collaborate and share intel on various projects, which she said has been the biggest business hurdle to date.

“Nobody wants to share,” Cahan said. “People are so afraid to tell you what they’re working on in case you might steal that idea. And I think that every idea right now is so great and important in this industry.”

“I believe that the power of this industry is going to be built on relationships, just like every other industry, and that you shouldn’t be afraid to share your homework, if you will, with me. And I’m looking for great partners all the time,” she said.

When she looks to the future, Cahan said she’s eager for women to stake more of a claim in the industry.

“I’m looking for women to actually enter this market. In my opinion, women have not entered cannabis. 60% of the market is flower, smokers. Women don’t want to smoke,” Cahan said. “But give me something that is going to help my body, that’s fast acting, that gives me a smoker’s high, and I’m in.”

The post Green Market Report Midwest Women in Cannabis Awards: Jackie Cahan appeared first on Green Market Report.

A new guidebook examines possible avenues to regulating the nonmedical use of psychedelics, including psilocybin, LSD, DMT and mescaline, encouraging policymakers to take a thoughtful, evidence-based approach to regulation—one that authors say is too often overlooked amid the “madness” of the global drug war.

“Regulating risky products and behaviors is just one of those things that governments around the world have been doing for generations, for centuries. And in many ways, they’re very good at it,” said Steve Rolles, senior policy analyst at the UK-based Transform Drug Policy Foundation, which published the new guide on Tuesday. Governments already weigh risks and benefits of all sorts of things, he noted, including pharmaceuticals, dangerous sports, consumer electronics, building materials and more.

“What Transform’s done with this book, and a lot of our work historically, is just apply that regulatory logic and that regulatory scholarship to a set of products and behaviors that have historically existed outside of regulatory thinking because of the madness of the war on drugs,” Rolles explained. “So it’s basically just applying social policy thinking and logic to this novel set of drugs and psychedelics.”

Most public policy discourse on psychedelics these days, Rolles noted, focuses on their medical use to treat conditions such as PTSD, depression and substance use disorders. But nonmedical use—including for recreation, religion and personal development—”has not received a great deal of attention,” he said, “and that’s one of the reasons we thought this book was needed.”

The focus on medical and therapeutic uses for psychedelics has driven public debate and fueled significant research, noted Ester Kincova, Transform’s public affairs and policy manager, but it also risks overlooking opportunities for reform around other types of use.

“There is a risk that this could lead to a space in which legitimate access to psychedelics is narrowly confined to the medical space,” she said. “People who are using psychedelics for other reasons may end up being left out.”

The 1st is a decriminalised private use model, that includes small-scale home cultivation, foraging, and not-for-profit sharing – activities that, by their nature, exist largely beyond the realm of formal regulation
1/ pic.twitter.com/eKUfaoFfa2

— Transform Drug Policy Foundation (@TransformDrugs) November 14, 2023

The 124-page document, titled “How to Regulate Psychedelics: A Practical Guide,” details four main tiers of psychedelics regulation. It advises against treating drugs like any other consumer product, for example by limiting advertising and establishing guidelines for who can supervise facilitated use. Transform has previously published similar guides around cannabis, cocaine, MDMA and amphetamines.

The four tiers of proposed psychedelics regulation begin with what’s essentially noncommercial legalization, allowing for home cultivation, foraging and not-for-profit sharing. It echoes the “grow, gather, gift” model advocated by many local psychedelics reformers in the U.S.

As the tiers progress, they involve more interventions by regulators, such as through licensing and antimonopoly protections.

The second tier is modeled after membership-based social clubs, nonprofit entities that provide regulated drug access to a limited number of members.

“We propose this model based on the cannabis social clubs that have been pioneered in Spain,” Kincova explained. “Although this is a relatively new and evolving model, there are several examples of established practices in Spain, Uruguay, Malta and other jurisdictions.” A centralized regulatory authority would license the clubs, which could potentially produce or import substances for distribution.

The 3rd model is a more conventional regulated retail model, providing adult-only sales for personal use for a range of quality-controlled products (plant & synthetic) from specialist licensed vendors (physical & online stores).
3/ pic.twitter.com/PaG8MUmkH4

— Transform Drug Policy Foundation (@TransformDrugs) November 14, 2023

The third and fourth tiers of regulation in Transform’s new guidebook deal with commercial drug markets. At the third level are licensed production and retail businesses, which would be regulated in ways meant to promote public safety and reduce drugs’ appeal to children. Advertising would be mostly forbidden, with only safety and potency information on product packaging, and infused edibles designed to look like candy or other appealing treats would be forbidden.

“Generally we don’t think there should be any marketing or branding,” Rolles said. “Our things was, if you start to put any design elements on it, you’re going to influence people’s experience… So let’s just keep it as simple and functional as possible.”

As for infused edibles, he called them “a terrible idea,” noting the confusion caused in some markets by cannabis edibles that resemble everyday consumer snacks. “If you really like sweets,” Rolles said, “just buy some fucking Haribo.”

Rolles likened the third tier to more tightly regulated retail marijuana markets, such as Quebec’s state-run stores.

The fourth regulator tier deals with facilitated use of psychedelics, an approach used in some therapeutic systems, such as in Oregon. Transform says such activities require establishing an institutional regulatory framework.

“We think there is an issue of a duty of care for people who are having guided experiences that really requires properly trained and licensed practitioners administering and supervising this kind of use,” Rolles said, noting that facilitated use can raise vulnerability and exploitation concerns or even lead to health emergencies. Steps also need to be taken, he said, to curb false or misleading medical claims.

Rolles said he believes the four tiers can “operate happily in parallel” to accommodate a variety of circumstances and cultural practices. Regulators might permit home cultivation or foraging of psilocybin mushrooms, for example, while also regulating facilitated use of LSD or DMT at commercial facilities.

The book explores the details, context & rationale for each of these models, also exploring issues around preventing corporate capture in emerging markets, equity & social justice, religious & Indigenous use, & challenges of international law.
5/ pic.twitter.com/66Noup3HMz

— Transform Drug Policy Foundation (@TransformDrugs) November 14, 2023

In addition to setting rules, Transform says regulators must monitor markets as they develop and track social indicators of health and drug use, both before and after any policy change.

One theme the Transform authors touched on repeatedly at Tuesday’s presentation was the role of commercial businesses in the psychedelic space. While the proposed regulatory models do contemplate for-profit entities, they also recommend noteworthy limits, including on branding and advertising, product packaging and market share.

“A vast amount of speculative investor capital is already flowing into the psychedelics market,” Kincova said, “and therefore any policy design must be alive to this risk and ensure any future regulatory frameworks for psychedelics are designed to prevent the emergence of these monopolies.”

Such steps might include limiting the number of production or retail licenses any one entity can control, as some legal cannabis markets already do, or establishing alternative, noncommercial models.

Embedded in any regulatory model should be strong equity and justice provisions, the Transform guide says.

“One of the key elements of any new emerging market is that it’s an opportunity to be ambitious about how you set it out,” Kincova said on Tuesday. “We believe equity programs should be available across all spectrums of these models.”

Equity programs should include removal of financial barriers for equity applicants, prioritizing them in the licensing process and providing them wraparound services such as legal, accounting and workforce training assistance. “All of these are extremely vital,” Kincova said, “but they also must be underpinned by continuous review of these programs to ensure that they are achieving their stated outcomes.”

On the topic of international drug treaties, which some observers have raised as potential obstacles to countries changing their domestic approach to regulating substances such as marijuana, Rolles said the compacts wouldn’t stand in the way of regulated markets for plant-based psychedelics, although there may be issues around synthetics such as LSD.

Transform’s new guidebook is available in print and as a free PDF at the organization’s website.

Rolles said the document is targeted at policymakers but will likely be of interest to anyone interested in what comes after the drug war.

“It’s not enough just to say the war on drugs is rubbish,” he said. “You can’t just get rid of it. You have to have something to replace it, and it has to be something credible, coherent, you know, that fits in with policymakers’ value systems and something that they can sell to their citizens and their electorate.”

Transform’s guidance comes less than a month after a coalition of international advocates called to end prohibition and instead legalize and regulate all drugs. That report, produced in partnership with the National Coalition for Drug Legalization (NCDL), Students for Sensible Drug Policy (SSDP) and Law Enforcement Action Partnership (LEAP), argued that “a legal and regulated market for drugs is likely to produce less dangerous outcomes for both society at large and the individuals who choose to consume drugs.”

Another report published last month by the International Coalition on Drug Policy Reform and Environmental Justice attacked the global drug war from an entirely different perspective, arguing that prohibition has ravaged critical ecosystems, undermined efforts to combat climate change and caught up vulnerable populations in a cycle of poverty and prosecution.

All three documents come amid a changing global mindset around substances. A United Nations agency report in September highlighted human rights concerns raised by the war on drugs, urging member states to shift from punitive drug-control policies to an approach rooted in public health. Dealing with drugs as a criminal problem, it said, is causing further harm.

UN experts and global leaders echoed those points in June as part of World Drug Day.

In 2019, the UN Chief Executives Board, which represents 31 UN agencies including the UN Office on Drugs and Crime (UNODC), adopted a position stipulating that member states should pursue science-based, health-oriented drug policies “including the decriminalization of drug possession for personal use.”

Latin American and Caribbean countries also recently agreed to rethink the drug war. Under the current, punitive approach, “the expected results have not been obtained when combating the world drug problem, leaving in many cases the underlying problems to be solved and exploiting and exacerbating vulnerabilities of our territories and societies,” according to a joint statement issued by 19 nations.

Nevertheless, a recent report by the organization Harm Reduction International found that wealthy countries gave nearly $1 billion to further the global drug war.

Massachusetts Governor Files Bill To Create Psychedelic Therapy Working Group For Veterans As Activists Push Legalization On Ballot

Photo courtesy of Wikimedia/Mädi.

The post New Guide On ‘How To Regulate Psychedelics’ Lays Out Four-Tiered Model Focused Specifically On Nonmedical Use appeared first on Marijuana Moment.

Although social equity as a concept is still relatively new in the cannabis industry – it only truly caught on around 2018 – it quickly became so entrenched that it’s now tough for state regulators to put together new industry models without including some version of equity.

If anything, social equity will only continue having a major impact on who is able to win business licenses in various state markets, along with how cannabis tax money is used to repair and invest in minority communities, policy experts told Green Market Report.

This stems in large part from the long and well-documented history of law enforcement disproportionately using marijuana prohibition against Black and brown Americans.

Social equity has been a significant feature in the rollout and licensure of most of the recent adult-use marijuana markets that have launched, noted DeVaugh Ward, senior legislative counsel at the nonprofit Marijuana Policy Project. As examples, he pointed to social equity programs tied directly to cannabis licensure in:

• Arizona
• Connecticut
• Illinois
• Maryland
• Missouri
• New Jersey
• New York
• Rhode Island

In addition, Hawaii lawmakers are also considering social equity as they weigh recreational legalization, he added.

Equity may even come into play once Congress can get its act together enough to agree on some form of federal cannabis legalization. Social equity has been embraced as a cause by several powerful Democrats, such as Sen. Cory Booker and Rep. Jerry Nadler. Both senators have pushed for versions of social equity to be included in cannabis bills they’ve sponsored, such as the SAFER Banking Act and the MORE Act.

“It’s one of those things that has certainly picked up as legalization has progressed. When the fight first started … the hurdle was just getting lawmakers to see that legalization was sound policy,” said MPP’s Ward.

“Since then, the goal posts have moved,” he said. “Now we’re not just debating whether legalization is sound policy; we’re also adding these other policy features that hope to make the industry more equitable.”

Differing Structures, Provisions

Because social equity is so new and because every U.S. state market has its own unique structure, no two states or social equity programs are truly the same.

Part of the problem is that program implementation is often followed by litigation, since such programs need to have qualifying criteria that necessarily leave certain entrepreneurs out in the cold. Those left out of the eligibility pools often decide to sue, and lawsuits can have a variety of effects, from courts ordering that regulators increase the number of available permits to temporarily halting licensing to throwing out social equity criteria.

New York is a prime example of how a well-intentioned social equity program has gone sideways, Ward said. There lawmakers and regulators both set out to establish a recreational marijuana market underpinned by social equity, and the first licenses were given to distressed hemp farmers and “justice-involved” retail entrepreneurs who had nonviolent criminal cannabis records.

The first lawsuit to tangle the rollout was from another social equity entrepreneur upset that he wasn’t eligible because he wasn’t a New York resident. After that was resolved, another lawsuit from several disabled military veterans – another demographic of social equity license hopefuls – wound up throwing into limbo almost all of the state’s 463 recreational permits issued as of August.

“You’re seeing it in New York, where folks are suing. It happened in Illinois, where folks sued. It was threatened in Massachusetts, when Massachusetts was considering making the delivery licenses equity-only,” Ward said.

In addition, social equity advocates acknowledge that a particular shortcoming of most programs has been tying reparations for the war on drugs directly to cannabis business licenses rather than taking a broader approach. Options for that could include state-funded programs for small business loans, technical assistance for entrepreneurs, job training for workers, or simply reinvestment money for minority communities to use as they see fit.

That’s an area where some believe the social equity movement will change in coming years as the concept is further refined.

“I actually think there should be a bit of a shift away from licensure,” said Amber Littlejohn, former president of the Minority Cannabis Business Association who is now an attorney in private practice.

“We have to revisit what’s being done with cannabis dollars, and (with) investing those dollars more holistically in programs that directly affect and can help remedy the consequences of prohibition,” she said. “Whether that be job training, mental health services, small business loans, looking beyond the immediate and helping to restore these communities is going to be important.”

That’s something that the current head of the MCBA, Kaliko Castille, said many advocates are already focused on: diversifying social equity programs themselves and changing the narrative from license-only benefits to other types of support, such as what Littlejohn described.

“The next leap is not having to just have the carve-out for licenses, but for there to be a true low barrier to entry, and for (social equity participants) to be able to get access to low-interest loans and training programs and technical assistance,” Castille said.

Ward said that’s why he and others have been pushing for broader social equity programs in places like Connecticut, where lawmakers wrote business incubator programs, job training funding, and other such assistance into the marijuana social equity program.

That should extend to the expungement of nonviolent cannabis criminal records, he added, which is another topic where the reform movement has had mixed results across the country.

Social equity is, at its core, “restorative justice for folks who were impacted by the war on drugs,” Ward emphasized. “The back end is the community reinvestment, and we consider expungement part of social equity.”

Obstacles Remain

The other reality that social equity advocates have to take into account, according to both Littlejohn and Ward, is politics.

So far, most social equity programs have found support in traditionally liberal states with Democratic leaders. The same has held true in Congress, where it’s Democrats that have taken the lead on cannabis reform and social equity, while Republicans in general have balked at giving any sort of special treatment to a given demographic.

“The political landscape … makes equity challenging,” Littlejohn said.

“It can’t be called equity,” she said. “It has to be wrapped up in a nice brown paper package. Open it up, and surprise, it’s equity, as opposed to coming, right hand fist raised, saying ‘We’re doing this for the people.'”

The same dynamic is true in Congress, where there’s been Republican pushback to including equity-centered provisions in measures such as the SAFER Banking Act, Littlejohn noted.

But it’s also very real on a state level, Castille pointed out, using Florida as an example. While the Sunshine state doesn’t have a social equity program per se, it had to issue a number of medical marijuana business permits for Black farmers as the direct result of a lawsuit.

However, the overall political environment of the state makes pushing a social equity agenda even more difficult.

“Right now, we’re living in a time when Florida is banning diversity, equity, and inclusion,” Castille said. “We’re dealing with a massive backlash … against what people on the right are deeming to be ‘woke’ policies.”

Another major hurdle could also prove to be the conservative-leaning U.S. Supreme Court, Ward said, which earlier this year struck down affirmative action policies in college admissions. The same kind of antipathy toward race-based policies could be used against social equity programs, Ward said.

He’s heard the ruling is already having ripple effects, causing lawmakers and their aides to reconsider both the implementation of social equity and how the programs are structured.

“The state of social equity policies is certainly in jeopardy, with the recent ruling out of the Supreme Court, a lot of folks are worried about social equity programs and the legality and the constitutionality,” Ward said. “I know that policymakers are looking at that ruling. I know attorneys general are looking at that ruling when they’re helping lawmakers craft legalization bills.”

And that’s going to be a very tricky policy situation moving forward, Castille said, precisely because the social equity movement is inextricably tied to race.

“What we’re trying to do is undo 90 years of racially motivated policies, and we’re trying to do it in small time frames,” Castille said. “These racial-based policies need to be undone in non-racial based ways.”

The post Social Equity Here to Stay in Marijuana Reform appeared first on Green Market Report.

A top federal health agency has released its latest annual survey on drug use trends. And for this latest round, it made a series of notable changes to the national questionnaire’s marijuana section that are meant to account for the evolving cannabis policy landscape—including new questions inquiring about modes of consumption such as vapes, edibles, dabs, lotions and CBD products.

The Substance Abuse and Mental Health Services Administration’s (SAMHSA) 2022 National Survey on Drug Use and Health (NSDUH) that was released on Monday—shared on X (formerly Twitter) by U.S. Department Health and Human Services (HHS) Secretary Xavier Becerra at precisely 4:20pm ET—now contains updated data on cannabis use trends that distinguish between marijuana and hemp products, explore different modes of consumption and ask more detailed questions about frequency of use.

The National Survey on Drug Use and Health (NSDUH) has helped us to understand substance use and mental health in this nation for the last 50 years.

Short on the report's findings and the need for the proper funding & commitment that @POTUS' supplemental request calls for

— Secretary Xavier Becerra (@SecBecerra) November 13, 2023

“The market information for marijuana section was revised to focus on purchases of marijuana or cannabis products rather than other ways in which people might have obtained these products,” SAMHSA said in its overview. “This revision allowed for more accurate reporting of marijuana and cannabis purchases in states that have decriminalized or legalized marijuana.”

Overall, the main crux of the survey showed that past-use cannabis trends held largely stable and didn’t deviate significantly in 2022 compared to the prior year. There has been a slight uptick compared to 2019 and 2020 levels, however, which may be partly attributable to lessened social restrictions that were enforced during the height of the COVID-19 pandemic.

One of the most notable data points from the updated questionnaire concerns methods of consumption. Respondents were asked, for the first time, whether they used cannabis by smoking, vaping, dabbing, eating or drinking, administering sublingually, using lotions or creams, taking pills or some alternative method.

“Respondents could report that they used marijuana in more than one way in the past year or past month,” SAMHSA said. “For example, respondents could report that they smoked marijuana and vaped it in the past year.”

“The complete list of modes of marijuana in the survey questions include smoking; vaping; dabbing waxes, shatter, or concentrates; eating or drinking; putting drops, strips, lozenges, or sprays in their mouth or under their tongue; applying lotion, cream, or patches to their skin; or taking pills. Respondents were also given an opportunity to describe other ways that they may have used marijuana that do not appear on the list.”

The survey found that, in 2022, the most common method of consumption in the past year among people 12 and older was smoking (78 precent), followed by eating or drinking infused products (47 percent), vaping (37 percent), dabbing (18 percent) and other (15 percent), which could refer to products like lotions, patches, pills and lozenges.

Marijuana remains the most commonly used federally illicit drug, with past-year use at 22 percent and past-month use at 15 percent among those 12 and older in 2022. That’s up from 19 percent and 13.2 percent, respectively, in 2021.

The survey shows that 6.4 percent of teens aged 12-17 reported using marijuana in the past month for 2022, which is a slight increase from 6.1 percent the prior year, but it’s still down from the 7.4 percent rate in 2019.

In general, the data shows that youth consumption has been relatively stable as more states have enacted adult-use legalization—a finding that advocates say reinforced the idea that establishing regulated markets that require ID for sales is an effective deterrent, despite claims of prohibitionists that reform would lead to a spike in underage use.

Still, Kevin Sabet of the prohibitionist organization Smart Approaches to Marijuana (SAM), however, asserted that the data shows “marijuana use skyrocketing among all ages.”

To little fanfare, some devastating news out of @samhsa's NSDUH today, the country's benchmark dataset for drug use – marijuana use skyrocketing among all ages — massive jumps among 12-13-14-15 year olds. More tomorrow but for now: https://t.co/j2usUN9N98 pic.twitter.com/56Hbezk2Fu

— Kevin Sabet (@KevinSabet) November 14, 2023

“This is what billions in lobbying, marketing and product development buy—more users and more addiction,” Sabet said in a press release. “The latest data from HHS makes clear what we’ve said all along, the normalization and industrialization of today’s high potency THC drug products is bad for Americans of all ages, especially our next generation.

The revised survey also asked about the use of federally legal hemp-derived CBD products, and it showed that about 11 percent of people 12 and older reported past-month use of the non-intoxicating cannabinoid. This marks the first time that the NSDUH asked about CBD, so there’s not a benchmark for comparison.

The secretary of HHS shared the new survey at 4:20pm ET on Monday—timing that seems to play into cannabis culture given both the symbolism of the number 420 within the community and Becerra’s tendency of posting about marijuana news at that exact time.

“The National Survey on Drug Use and Health provides an annual snapshot of behavioral health nationwide,” Becerra said in a press release. “This data informs knowledge, policy and action, and drives our shared commitment across government, healthcare, industry and community to offer resources and services to those in need.”

The cannabis product additions to the survey also seem consistent with a broader theme across the federal government, with agencies increasingly incorporating more robust marijuana-related data into their work as state markets continue to emerge and evolve.

For instance, the U.S. Census Bureau recently released its first report on state-level cannabis tax revenue data following what the agency calls “a complete canvass of all state agencies” going back to July 2021.

Returning to underage marijuana use, the SAMHSA survey indicates a slight uptick for 2022, but the overall trend has been relatively stables amid the state-level legalization movement. That’s consistent with a growing body of research on the topic.

For example, an analysis from the Centers for Disease Control and Prevention (CDC) that was released in May found that rates of current and lifetime cannabis use among high school students have continued to drop amid the legalization effort.

What was especially notable about the data is that it found high school student use was trending up from 2009-2013—before legal marijuana dispensaries started opening—but has been generally on the decline since then. The first state recreational legalization laws were approved by voters in 2012, with regulated retail sales beginning in 2014.

An American Medical Association (AMA) study published in September found “significant reductions” marijuana use by young adults following state-level legalization, although consumption did tick up slightly among young adults who claimed not to have ever tried marijuana prior to the policy change.

A separate federally funded study that was published in the American Journal of Preventive Medicine last year also found that state-level cannabis legalization is not associated with increased youth use.

The study demonstrated that “youth who spent more of their adolescence under legalization were no more or less likely to have used cannabis at age 15 years than adolescents who spent little or no time under legalization.”

Yet another federally funded study from Michigan State University researchers that was published in the journal PLOS One last year found that “cannabis retail sales might be followed by the increased occurrence of cannabis onsets for older adults” in legal states, “but not for underage persons who cannot buy cannabis products in a retail outlet.”

To that point, Colorado marijuana regulators announced last month that out of 285 underage sales checks conducted at state-licensed cannabis stores this year, there have been only four failures—a compliance rate of about 99 percent.

A study published last May in the Journal of Safety Research utilized underage operatives to determine how consistently California dispensaries abide by the law and require ID before proceeding with adult-use marijuana transactions. The analysis, based on visits to 90 shops across the state, showed 100 percent compliance.

In Oregon in 2017, 100 percent of marijuana stores passed an underage youth sales sting operation.

A recent Gallup poll, meanwhile, found that fully half of all American adults have tried marijuana at some point in their lives, with rates of active cannabis consumption surpassing that of tobacco. Broken down by age, 29 percent of those 18 to 34 say they currently smoke marijuana, though that’s not necessarily representative of overall cannabis use because the survey only asked about smoking and not other forms of consumption.

Another Texas City Will See Marijuana Decriminalization On Ballot After Lubbock Lawmakers Reject Voter Initiative

The post Federal Health Agency Releases Revised Drug Survey With New Data On Marijuana Product Preferences And CBD appeared first on Marijuana Moment.